Literature DB >> 19415468

Local controlled delivery of anti-neoplastic RNAse to the brain.

Joram Slager1, Betty Tyler, Ariella Shikanov, Abraham J Domb, Kuslima Shogen, David Sidransky, Henry Brem.   

Abstract

PURPOSE: Antineoplastic RNAse proteins, also known as Amphibinases, have been shown effective against various solid tumors but were found selectively neurotoxic to Purkinje cells in the cerebellum. This work describes the use of a waxy biodegradable poly(ricinoleic-co-sebacic acid) for the local controlled delivery of cytotoxic amphibinases in the parietal lobe of the brain in an attempt to overcome cerebellar neuronal toxicity while affecting glioma cells.
METHODS: Amphibinase analogues were encapsulated in poly(ricinoleic-co-sebacic acid) formulations using mix-melt technology and loaded onto surgical foam. In-vitro release was monitored by BCA colorimetry and by RNAse specific bioactivity. The implants were inserted into rat brains bearing 9L glioma to assess toxicity and efficacy.
RESULTS: The various formulations showed extended linear release for several weeks with minimal burst effect. Best in-vivo efficacy was obtained with ACC7201 containing implants, resulting in the extension of the median survival from 13 to 18 days with 13% long-term survivors.
CONCLUSION: Antineoplastic proteins were released from a p(SA-RA) polyanhydride implants in a controlled manner, providing efficacy against 9L glioma, while evading neurotoxicity in the cerebellum. The controlled release of Amphibinases forms the potential for a new therapy against brain tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415468      PMCID: PMC3085080          DOI: 10.1007/s11095-009-9893-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

Review 1.  Natural and engineered cytotoxic ribonucleases: therapeutic potential.

Authors:  S M Rybak; D L Newton
Journal:  Exp Cell Res       Date:  1999-12-15       Impact factor: 3.905

2.  Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase.

Authors:  H D Halicka; T Murakami; C N Papageorgio; A Mittelman; S M Mikulski; K Shogen; Z Darzynkiewicz
Journal:  Cell Prolif       Date:  2000-12       Impact factor: 6.831

Review 3.  Targeted therapy for brain tumours.

Authors:  Maciej S Lesniak; Henry Brem
Journal:  Nat Rev Drug Discov       Date:  2004-06       Impact factor: 84.694

4.  Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors.

Authors:  J Hanes; A Sills; Z Zhao; K W Suh; B Tyler; F DiMeco; D J Brat; M A Choti; K W Leong; D M Pardoll; H Brem
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

5.  Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer.

Authors:  Shinichi Tsutsui; Akemi Kataoka; Shinji Ohno; Shigeru Murakami; Junko Kinoshita; Yoichi Hachitanda
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

6.  Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.

Authors:  Francesco DiMeco; Khan W Li; Berry M Tyler; Ariel S Wolf; Henry Brem; Alessandro Olivi
Journal:  J Neurosurg       Date:  2002-11       Impact factor: 5.115

7.  Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

Authors:  Stanislaw M Mikulski; John J Costanzi; Nicholas J Vogelzang; Spence McCachren; Robert N Taub; Hoo Chun; Abraham Mittelman; Timothy Panella; Carmelo Puccio; Robert Fine; Kuslima Shogen
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

8.  Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.

Authors:  James L Frazier; Paul P Wang; Daniel Case; Betty M Tyler; Gustavo Pradilla; Jon D Weingart; Henry Brem
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

9.  The cytotoxic ribonuclease onconase targets RNA interference (siRNA).

Authors:  Hong Zhao; Barbara Ardelt; Wojciech Ardelt; Kuslima Shogen; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2008-10-25       Impact factor: 4.534

10.  Comprehensive comparison of the cytotoxic activities of onconase and bovine seminal ribonuclease.

Authors:  Josef Matousek; Josef Soucek; Tomás Slavík; Milan Tománek; J Eugene Lee; Ronald T Raines
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2003-12       Impact factor: 3.228

View more
  1 in total

1.  Biohybrid polymer-antimicrobial peptide medium against Enterococcus faecalis.

Authors:  Lea H Eckhard; Asaf Sol; Ester Abtew; Yechiel Shai; Abraham J Domb; Gilad Bachrach; Nurit Beyth
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.